Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
RMC-5552 selectively inhibits mTORC1, resulting in decreased downstream signaling and potentially leading to reduced growth and increased apoptosis in tumor cells (European Journal of Cancer 138 (2020): S1-S62).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|RMC-5552||RMC5552|RMC 5552||mTORC1 Inhibitor 9||RMC-5552 selectively inhibits mTORC1, resulting in decreased downstream signaling and potentially leading to reduced growth and increased apoptosis in tumor cells (European Journal of Cancer 138 (2020): S1-S62).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN inact mut||head and neck cancer||predicted - sensitive||RMC-5552||Case Reports/Case Series||Actionable||In a Phase I/Ib trial, RMC-5552 treatment resulted in an objective response rate of 20% (1/5) and 3 stable disease in patients with advanced solid tumors, with 1 partial response observed in a patient with head and neck cancer harboring a pathogenic PTEN mutation (J of Clin Oncol40, no. 16_suppl (June 01, 2022) 3098; NCT04774952).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05557292||Phase I||RMC-5552||RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma||Active, not recruiting||USA||0|
|NCT04774952||Phase I||RMC-5552||Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors||Recruiting||USA||0|